Skip to main content
17 search results for:

Ertugliflozin  ertugliflozin (investigational)

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 09-24-2020 | EASD 2020 | Conference coverage | Article

    Further VERTIS-CV analysis supports ertugliflozin renal benefits

    By month 60 there was a significant difference of 2.55 mL/min per 1.73 m 2 between the two groups, favoring ertugliflozin.

  2. 10-12-2020 | Ertugliflozin | News | Article

    VERTIS CV secondary analyses indicate ertugliflozin protection against HF

    Secondary analysis of the VERTIS CV trial supports a significant protective effect of ertugliflozin on risk for heart failure in people with type 2 diabetes, despite the overall neutral outcome of the trial.

  3. 06-16-2020 | ADA 2020 | Conference coverage | Article

    VERTIS-CV: Similar MACE risk with ertugliflozin vs placebo in type 2 diabetes

    Patients with type 2 diabetes and established atherosclerotic disease who are treated with the SGLT2 inhibitor ertugliflozin have a similar risk for major adverse cardiovascular events to those given placebo, shows the VERTIS-CV trial.

  4. 01-08-2018 | Ertugliflozin | Article

    Ertugliflozin and sitagliptin co-initiation in patients with type 2 diabetes: The VERTIS SITA randomized study

    Ertugliflozin is an oral sodium-glucose cotransporter 2 inhibitor that is being developed to treat type 2 diabetes mellitus (T2DM).

  5. 11-20-2017 | Ertugliflozin | Article

    Ertugliflozin in patients with stage 3 chronic kidney disease and type 2 diabetes mellitus: The VERTIS RENAL randomized study

    Ertugliflozin is a sodium-glucose cotransporter 2 inhibitor in development for type 2 diabetes mellitus (T2DM).

  6. 12-27-2017 | Ertugliflozin | Article

    Ertugliflozin compared with glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin: The VERTIS SU randomized study

    This study assessed the safety and efficacy of ertugliflozin (an oral sodium-glucose cotransporter 2 inhibitor) vs. glimepiride in patients with type

  7. 11-21-2017 | Topic page

    Ertugliflozin

  8. 08-29-2021 | ESC 2021 | News | Article

    Metformin use may not influence SGLT2 inhibitor effect

    Post-hoc analysis of the VERTIS-CV trial indicates that the cardiovascular effects of ertugliflozin are unaffected by whether people are also taking metformin.

  9. 10-01-2021 | EASD 2021 | News | Article

    Use of SGLT2 inhibitors beneficial in older adults with type 2 diabetes

    The real-world study included 450 adults at least 70 years of age with type 2 diabetes who started on an SGLT2 inhibitor, most commonly empagliflozin (47.6%), followed by dapagliflozin (41.6%), canagliflozin (9.1%), and ertugliflozin (1.7%).

  10. 06-24-2020 | ADA 2020 | Conference coverage | Article

    ADA 2020 goes virtual! Editorial Board conference highlights

    Listen to our Editorial Board reflecting on their ADA scientific highlights, and its novel virtual format (34:17).

  11. 06-12-2017 | Medications | News | Article

    Research round-up: medications for type 2 diabetes

    Inc, Chicago, Illinois, USA), tested ertugliflozin in patients with poor glycemic control on metformin plus sitagliptin.

  12. 05-06-2019 | SGLT2 inhibitors | News | Article

    Postmarketing data support Fournier gangrene link with SGLT2 inhibitors

    Cases of Fournier gangrene occurred in patients using all SGLT2 inhibitors apart from ertugliflozin, which the researchers attribute to the latter’s relatively short length of time on the market – just over a year at the time of the analysis.

  13. 11-28-2018 | SGLT2 inhibitors | Commentary | Article
    Expert commentary

    What can real-world studies really tell us about amputation risk for SGLT2 inhibitors?

    So far, there is no convincing evidence suggesting that empagliflozin or dapagliflozin increase amputation risk, but until more evidence emerges, in particular from the ongoing VERTIS trial with ertugliflozin, and ongoing trials in renal impairment and heart failure with dapagliflozin and empagliflozin, it is wise for clinicians to avoid using SGLT2 inhibitors in patients with previous amputations or existing foot ulceration.

  14. 04-16-2018 | Type 1 diabetes | Review | Article

    The potential role of SGLT2 inhibitors in the treatment of type 1 diabetes mellitus

    Fattah H, Vallon, V. Drugs 2018; 78: 717–726. doi: 10.1007/s40265-018-0901-y

  15. 03-27-2018 | Nephropathy | Review | Article

    New diabetes therapies and diabetic kidney disease progression: The role of SGLT-2 inhibitors

    Dekkers CCJ, Gansevoort RT, Heerspink HJL. Curr Diab Rep 2018; 18: 27. doi: 10.1007/s11892-018-0992-6

  16. 10-11-2017 | Cardiovascular disorders | Review | Article

    Updates on cardiovascular outcome trials in diabetes

    Schnell O et al. Cardiovasc Diabetol 2017; 16: 128. doi: 10.1186/s12933-017-0610-y

  17. 07-01-2015 | Type 2 diabetes | Review | Article

    Pharmacokinetics, pharmacodynamics and clinical use of SGLT2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease

    Scheen AJ. Clin Pharmacokinet 2015; 54: 691–708. doi: 10.1007/s40262-015-0264-4

  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.